Access to HIV/AIDS Pharmaceuticals and Medical

This executive order directs the U.S. to refrain from using trade pressure to challenge intellectual property laws in sub-Saharan African countries that promote access to HIV/AIDS medicines while still complying with international TRIPS standards. It also encourages these countries to implement broader prevention and health infrastructure policies.

Federal Register Open PDF 65 FR 30521

Key directives

U.S. shall not seek revocation or revision of HIV/AIDS-related IP laws in beneficiary sub-Saharan African countries that promote access and comply with TRIPS
U.S. shall encourage beneficiary countries to implement prevention, health infrastructure, and R&D incentive policies
Prohibition on Section 301(b) actions against qualifying laws
Explicit reservation of WTO dispute settlement procedures
Explicit reservation of U.S. right to evaluate and express concerns about qualifying laws

Timeline

Immediate

U.S. prohibited from Section 301 actions against qualifying African IP laws on HIV/AIDS medicines
U.S. officials may continue evaluating and consulting on such laws

Near term (90d)

Ongoing U.S. encouragement of African prevention and health infrastructure policies

Long term

Sustained U.S. support for HIV/AIDS vaccine development
Partnership-building among governments, NGOs, and private sector

Risks & tensions

Tension between pharmaceutical industry IP interests and public health access goals—text attempts balance via TRIPS compliance requirement
WTO dispute settlement reservation (Sec. 3(a)) creates ambiguity: U.S. retains formal leverage while forgoing unilateral Section 301 pressure
No enforcement mechanism or private right of action (Sec. 3(b)); durability depends on executive branch adherence
Vague standard for 'adequate and effective' IP protection leaves discretion to U.S. officials, potential for inconsistent application
Beneficiary country status determined by President, creating political variability